BlueWhale Bio, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
BlueWhale Bio, Inc. - overview
Established
2023
Location
Philadelphia, PA, US
Primary Industry
Biotechnology
About
Based in Pennsylvania, US, and founded in 2023, BlueWhale Bio, Inc. is a spinout from the University of Pennsylvania and operates as a biotechnology company that develops platforms for the delivery of cell and gene therapy. In September 2023, BlueWhale Bio raised USD 18 million in seed funding led by Danaher Corporation, with participation from Novalis LifeSciences and Hillhouse Capital Group. As of September 2023, the company is led by its CEO Peter Keller.
BlueWhale Bio, Inc. developing a technology platform aimed at accelerating the delivery of cell and gene therapy benefits to patients while simultaneously reducing costs. The company plans to use the seed funding to expand operations and its R&D sector.
Current Investors
Danaher Corporation, Hillhouse Investment, Novalis LifeSciences
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Medical Software
Verticals
HealthTech
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.